Clinical trial · Observational
Viscoelasticity Imaging to Assess Liver Cancer
Added Value of Shear Wave Viscoelasticity Imaging, Homodyned-K Tissue Imaging and Acoustic Attenuation to Assess Liver Cancer at Ultrasound: a Multiparametric Learning Approach
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 18, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260918-000001
Summary
Brief summary (as posted)
Ultrasound (US) used for hepatocellular carcinoma (HCC) surveillance suffers from low sensitivity (60-78%) due to fatty liver, obesity, and diffusely nodular appearance in cirrhosis. Once a suspicious malignant lesion is detected at US, guidelines recommend contrast-enhanced US, magnetic resonance imaging (MRI) or computed tomography (CT) scans to confirm suspicion. The investigators' team has developed innovative quantitative US (QUS) techniques that have a high potential to improve tissue characterization in terms of sensitivity and specificity. The investigators hypothesize that advanced QUS providing tumor viscoelasticity assessment, sub-resolution tissue structure characterization and US attenuation in the framework of a machine learning classification model can improve HCC diagnosis compared with standard US. Early detection through systematic US surveillance translates into curative therapy in a higher proportion of patients and into improvements in survival rates. Thus, there is an urgent need to investigate innovative and cost-effective imaging techniques for improving detection and characterization of HCC. The proposed QUS methods are experimental and will be validated in this proof-of-concept clinical study. A major impact of this work, for patients and medical institutions, will be to improve early-stage detection and characterization of HCC, and offer alternatives in patients with negative or inconclusive conventional US. QUS are low-cost, non-invasive and non-irradiating imaging modalities available from a single exam (i.e., no additional imaging session is necessary).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Viscoelastography | Device | — | UNRESOLVED |
| QUS | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Training cohort
- description
- All patients enrolled will undergo: * Magnetic Resonance Viscoelastography * Quantitative ultrasound (QUS)
- interventionNames
- Device: Magnetic Resonance Viscoelastography
- Device: QUS
- label
- Validation cohort
- description
- All patients enrolled will undergo: • Quantitative ultrasound (QUS)
- interventionNames
- Device: QUS
Primary outcomes (3)
- measure
- Liver viscoelastography determined by MRI
- timeFrame
- Within 6 weeks of liver echography
- description
- Measure of liver viscoelastography using magnetic resonance Imaging (MRI)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Are at least 18 years old at screening; * Able to comprehend and willingness to provide voluntary consent; * Are able to have a MRI; * Understand French or English; * Patients enrolled in a monitoring program or referred for the characterization of a focal liver lesion; * Focal liver lesion is visible during ultrasound screening in B-mode. Exclusion Criteria: * Are pregnant or trying to become pregnant; * Have a weight or girth preventing from entering the MR magnet bore; * Are unable to understand or unwilling to provide written informed consent for this study; * Have a contraindication to MRI (pacemaker, insurmountable claustrophobia); * Have chronic kidney disease preventing the injection of gadolinium-based contrast agent.
References
Publications (0)
Data not yet available